Fortress Biotech Company Profile (NASDAQ:FBIO)

About Fortress Biotech (NASDAQ:FBIO)

Fortress Biotech logoFortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:FBIO
  • CUSIP: 21976U10
  • Web:
  • Market Cap: $235.05 million
  • Outstanding Shares: 50,332,000
Average Prices:
  • 50 Day Moving Avg: $4.57
  • 200 Day Moving Avg: $3.57
  • 52 Week Range: $1.88 - $5.07
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.93
  • P/E Growth: -0.15
Sales & Book Value:
  • Annual Revenue: $60.5 million
  • Price / Sales: 4.05
  • Book Value: $0.95 per share
  • Price / Book: 5.13
  • EBIDTA: ($64,150,000.00)
  • Net Margins: -269.14%
  • Return on Equity: -63.99%
  • Return on Assets: -34.99%
  • Debt-to-Equity Ratio: 0.22%
  • Current Ratio: 2.88%
  • Quick Ratio: 2.87%
  • Average Volume: 230,130 shs.
  • Beta: 1.16
  • Short Ratio: 15.3
Frequently Asked Questions for Fortress Biotech (NASDAQ:FBIO)

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) released its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. The business had revenue of $2.78 million for the quarter, compared to the consensus estimate of $47.04 million. Fortress Biotech had a negative net margin of 269.14% and a negative return on equity of 63.99%. View Fortress Biotech's Earnings History.

Where is Fortress Biotech's stock going? Where will Fortress Biotech's stock price be in 2017?

5 analysts have issued 1-year price objectives for Fortress Biotech's shares. Their forecasts range from $9.00 to $11.00. On average, they expect Fortress Biotech's stock price to reach $10.60 in the next year. View Analyst Ratings for Fortress Biotech.

What are analysts saying about Fortress Biotech stock?

Here are some recent quotes from research analysts about Fortress Biotech stock:

  • 1. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (7/11/2017)
  • 2. FBR & Co analysts commented, "On May 10, Fortress reported 1Q17 results. The company did not host a conference call, but we had a chance to catch up with the CEO. We note that Fortress made great progress in terms of advancing its pipeline in 2017. Recent company highlights include the launch of two additional subsidiaries in the quarter, Caelum Biosciences and Cyprium Therapeutics, thereby broadening the company pipeline to include amyloid light chain (AL) amyloidosis and Menkes disease indications. We expect the company to continue to advance its pipeline and explore additional opportunities to strengthen its subsidiary company portfolio for the rest of 2017." (5/12/2017)

Who are some of Fortress Biotech's key competitors?

Who are Fortress Biotech's key executives?

Fortress Biotech's management team includes the folowing people:

  • Lindsay A. Rosenwald M.D., Chairman of the Board, President, Chief Executive Officer
  • Eric K. Rowinsky M.D., Vice Chairman of the Board
  • Robyn Hunter, Chief Financial Officer
  • Michael S. Weiss, Executive Vice Chairman - Strategic Development
  • Lucy Lu M.D., Executive Vice President
  • George C. Avgerinos Ph.D., Senior Vice President - Biologics Operations
  • Malcolm I. Hoenlein, Director
  • David J. Barrett CPA,, Independent Director
  • Jimmie Harvey Jr., M.D., Independent Director
  • J. Jay Lobell J.D., Independent Director

Who owns Fortress Biotech stock?

Fortress Biotech's stock is owned by a number of of institutional and retail investors. Top institutional investors include Abner Herrman & Brock LLC (0.21%). View Institutional Ownership Trends for Fortress Biotech.

Who bought Fortress Biotech stock? Who is buying Fortress Biotech stock?

Fortress Biotech's stock was acquired by a variety of institutional investors in the last quarter, including Abner Herrman & Brock LLC. View Insider Buying and Selling for Fortress Biotech.

How do I buy Fortress Biotech stock?

Shares of Fortress Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fortress Biotech's stock price today?

One share of Fortress Biotech stock can currently be purchased for approximately $4.87.

MarketBeat Community Rating for Fortress Biotech (NASDAQ FBIO)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  149
MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Fortress Biotech (NASDAQ:FBIO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.60 (117.66% upside)

Analysts' Ratings History for Fortress Biotech (NASDAQ:FBIO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/11/2017HC WainwrightSet Price TargetBuy$11.00HighView Rating Details
7/11/2017Rodman & RenshawInitiated CoverageBuy -> Buy$11.00LowView Rating Details
7/4/2017FBR & CoReiterated RatingBuyMediumView Rating Details
3/22/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$11.00MediumView Rating Details
10/3/2016Roth CapitalInitiated CoverageBuy$9.00N/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Fortress Biotech (NASDAQ:FBIO)
Earnings by Quarter for Fortress Biotech (NASDAQ:FBIO)
Earnings History by Quarter for Fortress Biotech (NASDAQ FBIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.36)($0.30)$47.04 million$2.78 millionViewN/AView Earnings Details
8/9/2016Q2($0.29)($0.31)$1.07 million$2.23 millionViewN/AView Earnings Details
5/10/2016Q1($0.31)$0.66 millionViewN/AView Earnings Details
3/15/2016Q4($0.09)($0.31)$0.34 millionViewN/AView Earnings Details
11/9/2015Q315($0.13)($0.46)$0.03 millionViewN/AView Earnings Details
8/10/2015Q2($0.16)ViewN/AView Earnings Details
5/11/2015Q1($0.31)ViewN/AView Earnings Details
3/16/2015Q414($0.10)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.17)($0.13)ViewN/AView Earnings Details
5/12/2014Q114($0.18)($0.21)ViewN/AView Earnings Details
3/14/2014Q413($0.22)($0.27)ViewN/AView Earnings Details
11/1/2013Q313($0.31)($0.24)ViewN/AView Earnings Details
8/5/2013Q213($0.31)($0.38)ViewN/AView Earnings Details
5/8/2013Q1 2013($0.30)($0.35)ViewN/AView Earnings Details
3/14/2013Q4 2012($0.27)($0.36)ViewN/AView Earnings Details
11/14/2012Q312($0.28)($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Fortress Biotech (NASDAQ:FBIO)
2017 EPS Consensus Estimate: ($1.47)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.33)($0.33)($0.33)
Q2 20171($0.37)($0.37)($0.37)
Q3 20171($0.38)($0.38)($0.38)
Q4 20171($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)


Dividend History for Fortress Biotech (NASDAQ:FBIO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Fortress Biotech (NASDAQ:FBIO)
Insider Ownership Percentage: 31.54%
Institutional Ownership Percentage: 12.91%
Insider Trades by Quarter for Fortress Biotech (NASDAQ:FBIO)
Institutional Ownership by Quarter for Fortress Biotech (NASDAQ:FBIO)
Insider Trades by Quarter for Fortress Biotech (NASDAQ:FBIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/16/2016George AvgerinosSVPSell48,912$2.55$124,725.60View SEC Filing  
12/1/2014Lucy LuCFOBuy5,000$1.45$7,250.00View SEC Filing  
11/6/2014Lindsay A Md RosenwaldCEOBuy150,000$1.61$241,500.00View SEC Filing  
11/6/2014Malcolm HoenleinDirectorBuy25,000$1.61$40,250.00View SEC Filing  
11/6/2014Michael S WeissMajor ShareholderBuy1,000,000$1.61$1,610,000.00View SEC Filing  
6/2/2014Lucy LuCFOBuy5,000$1.37$6,850.00View SEC Filing  
4/22/2014Kevin HorganInsiderSell47,566$1.89$89,899.74View SEC Filing  
4/21/2014Kevin HorganInsiderSell19,000$1.81$34,390.00View SEC Filing  
8/21/2013J Jay LobellDirectorBuy5,000$7.37$36,850.00View SEC Filing  
7/17/2013Lucy LuCFOBuy4,545$7.90$35,905.50View SEC Filing  
6/20/2013J Jay LobellDirectorBuy10,000$7.62$76,200.00View SEC Filing  
5/31/2013Dale RitterCAOBuy1,503$3.88$5,831.64View SEC Filing  
5/31/2013Lucy LuCFOBuy4,979$3.88$19,318.52View SEC Filing  
5/31/2013Noah D BeermanCOOBuy5,000$3.88$19,400.00View SEC Filing  
1/14/2013Harlan F WeismanCEOBuy20,000$5.71$114,200.00View SEC Filing  
11/30/2012Glenn L Md CooperInsiderBuy3,811$4.02$15,320.22View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Fortress Biotech (NASDAQ:FBIO)
Latest Headlines for Fortress Biotech (NASDAQ:FBIO)
DateHeadline logoBRIEF-Fortress Biotech announces filing of provisional patent application for Caelum Biosciences' cael-101 - July 18 at 12:28 AM logoFortress Biotech Announces Filing of Provisional Patent Application for Caelum Biosciences’ CAEL-101 - July 17 at 11:54 AM logoFortress Biotech, Inc. (FBIO) Downgraded by Zacks Investment Research to Hold - July 12 at 12:04 AM logoFortress Biotech, Inc. (NASDAQ:FBIO) Receives Consensus Recommendation of "Buy" from Brokerages - July 11 at 8:26 AM logoReviewing Catalyst Biosciences (CBIO) & Fortress Biotech (NASDAQ:FBIO) - July 4 at 6:26 PM logoFortress Biotech (FBIO) Shares March Higher, Can It Continue? - June 30 at 6:51 PM logoAvenue Therapeutics Completes Initial Public Offering - June 30 at 11:40 AM logoPharmaceuticals Abound Among This Week's 11 IPOs - June 27 at 10:25 PM logoAvenue Therapeutics IPO Info - June 27 at 5:23 PM logoAvenue Therapeutics Prices Initial Public Offering of $33,000,000 of Common Stock - June 26 at 8:36 PM logoCheckpoint Therapeutics Commences Trading on the NASDAQ Capital Market - June 26 at 6:16 PM logoFortress Biotech to Present at the 2017 BIO International Convention - June 15 at 7:16 PM logoMeet This Week's IPOs: A Biotech, A BDC And A Builder - June 13 at 11:36 AM logoFortress Biotech, Inc. (FBIO) Upgraded to Buy by Zacks Investment Research - June 13 at 10:04 AM logoFortress Biotech Inc (FBIO) Upgraded to Hold by ValuEngine - June 7 at 3:32 PM logoFortress Biotech Announces that its Subsidiary, Mustang Bio, Enters into License Agreements with City of Hope for Novel CAR T Immunotherapies - June 5 at 11:19 AM logoFortress Biotech (FBIO) vs. Vitae Pharmaceuticals (VTAE) Head-To-Head Comparison - June 4 at 8:28 PM logoFortress Biotech (FBIO) Subsidiary Enters Biopharmaceutical Manufacturing Agreement With Patheon - June 1 at 5:52 PM logoFortress Biotech Subsidiary Caelum Biosciences Enters Biopharmaceutical Manufacturing Agreement With Patheon - June 1 at 5:52 PM logoCheckpoint Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference - June 1 at 5:52 PM logoA Profitable And Growing Microcap Investment Bank Focused On The Biotech Sector - May 31 at 10:07 PM logoAvenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol - May 19 at 4:53 PM logoFortress Biotech (FBIO) Looks Good: Stock Adds 5% in Session - May 19 at 4:53 PM logoFortress Biotech Inc (FBIO) Upgraded to Buy by Zacks Investment Research - May 15 at 8:58 PM logoETFs with exposure to Fortress Biotech, Inc. : May 15, 2017 - May 15 at 4:49 PM logoMustang Bio Reports First Quarter 2017 Financial Results and Recent Corporate Highlights - May 15 at 4:48 PM logoQ2 2017 EPS Estimates for Fortress Biotech Inc (FBIO) Boosted by FBR & Co - May 15 at 7:58 AM logoFortress Biotech, Inc. :FBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 - May 12 at 5:41 PM logoFortress Biotech Inc (FBIO) Receives Buy Rating from FBR & Co - May 12 at 5:20 PM logoFortress Biotech Inc (FBIO) Issues Quarterly Earnings Results - May 11 at 7:36 PM logoFortress Biotech Reports First Quarter 2017 Financial Results and Recent Corporate Highlights - May 10 at 5:15 PM logoFortress Biotech reports 1Q loss - May 10 at 5:15 PM logoFortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis - May 4 at 12:30 PM logoFortress Biotech (FBIO) Receiving Somewhat Favorable News Coverage, Report Finds - May 1 at 4:48 PM logoFortress Biotech to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co. - April 27 at 11:24 AM logoCheckpoint Therapeutics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co. - April 27 at 11:24 AM logoFortress Biotech (FBIO) Getting Favorable News Coverage, Analysis Finds - April 24 at 10:46 AM logoMustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer - April 24 at 8:19 AM logoFortress Biotech (FBIO) Earning Negative Press Coverage, Report Shows - April 20 at 8:49 AM logoFortress Biotech (FBIO) Earning Very Positive News Coverage, Report Shows - April 16 at 8:10 AM logoFortress Biotech (FBIO) Presents At The 24th Annual Future Leaders in the Biotech Industry Conference - Slideshow - April 10 at 4:55 PM logoFortress Biotech's (FBIO) "Buy" Rating Reiterated at FBR & Co - April 7 at 10:07 PM logoCheckpoint Therapeutics Reports Preclinical Data for Two Oncology Programs - April 7 at 9:45 AM logoFortress Biotech Announces Orphan Drug Designations for CAEL-101 in Amyloidosis - April 7 at 9:45 AM logoFortress Biotech to Present at BioCentury’s 24th Annual Future Leaders in the Biotech Industry Conference - March 30 at 5:36 PM logoFortress Biotech Inc (FBIO) Cut to "Sell" at Zacks Investment Research - March 27 at 8:26 AM logoFORTRESS BIOTECH, INC. Financials - March 23 at 5:38 PM logoFortress Biotech Inc (FBIO) Now Covered by Analysts at JMP Securities - March 22 at 11:07 PM logoCoverage initiated on Fortress Biotech by JMP Securities - March 22 at 5:18 PM logoFortress Biotech Inc (FBIO) Cut to Sell at Zacks Investment Research - March 21 at 10:39 PM



Fortress Biotech (FBIO) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff